» Articles » PMID: 24258985

Tumor-infiltrating Lymphocytes and Their Significance in Melanoma Prognosis

Overview
Specialty Molecular Biology
Date 2013 Nov 22
PMID 24258985
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

The role of the tumor-infiltrating lymphocyte (TIL) and its relationship to prognosis has been most extensively studied in malignant melanoma. The purpose of this chapter is to discuss in depth the immunobiology and molecular aspects of lymphocyte function in general and particularly TIL function in the context of antimelanoma immunity. Emphasis is placed upon the role of these inflammatory mediators in the enhancement and impairment of progression of this often fatal human cancer. In addition, the analysis of TILs in melanoma and their direct relationship to prognosis as well as their effect on the positivity of the sentinel lymph node will be discussed. Furthermore, details of lymph node responses to metastatic melanomas and their prognostic significance will be clarified. Finally, the importance of TILs for the evaluation of therapeutic response and how TIL immunobiology could critically inform the design of novel melanoma immunotherapeutic protocols will be elucidated.

Citing Articles

Exploitation of Unconventional CD8 T-Cell Responses Induced by Engineered Cytomegaloviruses for the Development of an HIV-1 Vaccine.

Bruton J, Hanke T Vaccines (Basel). 2025; 13(1).

PMID: 39852851 PMC: 11769474. DOI: 10.3390/vaccines13010072.


Role of tumor-infiltrating lymphocytes in melanoma prognosis and treatment strategies: A systematic review and meta-analysis.

Garutti M, Bruno R, Polesel J, Pizzichetta M, Puglisi F Heliyon. 2024; 10(12):e32433.

PMID: 39183829 PMC: 11341338. DOI: 10.1016/j.heliyon.2024.e32433.


Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator.

Varey A, Li I, El Sharouni M, Simon J, Dedeilia A, Chng S J Clin Oncol. 2024; 42(10):1169-1180.

PMID: 38315961 PMC: 11003510. DOI: 10.1200/JCO.23.01020.


A novel molecular signature for predicting prognosis and immunotherapy response in osteosarcoma based on tumor-infiltrating cell marker genes.

Tang H, Liu S, Luo X, Sun Y, Li X, Luo K Front Immunol. 2023; 14:1150588.

PMID: 37090691 PMC: 10117669. DOI: 10.3389/fimmu.2023.1150588.


Modulating the proliferative and cytotoxic properties of patient-derived TIL by a synthetic immune niche of immobilized CCL21 and ICAM1.

Yunger S, Geiger B, Friedman N, Besser M, Adutler-Lieber S Front Oncol. 2023; 13:1116328.

PMID: 36937426 PMC: 10020329. DOI: 10.3389/fonc.2023.1116328.